Build or buy a biotech CRM, or use AI instead?

A CRM at forty people is a memory tax. Somebody logs the call, somebody sets the reminder, and the moment that person is busy for two weeks the record stops describing reality.

The biotech CRM question is not really a software question. It is a question about who is going to remember what was said to whom. Investors, partners, advisers, candidates, key opinion leaders and a handful of vendors all live in one founder's head and one inbox, and the reason people go shopping is that the head stopped being big enough somewhere around the twentieth intro call.

What a biotech CRM is actually being asked to do

Almost never sales automation. What a small biotech wants is four things: who is this person, what is our history, what did each of us promise, and what is the next move. A commercial-stage pipeline tool is built for a different job, which is why the field-heavy ones feel like overhead here and the light ones feel like a contact list with extra steps.

If your company is commercial and running field teams, the answer is different and larger, and it belongs on build or buy pharma CRM. The rest of this page is about the preclinical or clinical-stage company where business development is one or two people and neither of them has an operations function behind them.

The case for buying

Buy when more than one person genuinely needs the same view and will act on it, when you need reporting somebody else defines, or when a board or an investor expects a pipeline in a recognizable format. Those are legitimate reasons and the tools are cheap enough.

Just be honest about the failure mode before you sign. A CRM is a form, the form has to be fed, and at your headcount the feeder is the person with the least time. The record is then accurate immediately after each review and drifting the rest of the month. The same logic runs through the entire build vs buy software decision for a small company.

The case for building

Building a contact tracker is one of the most tempting internal projects there is, because it looks trivial. It usually is trivial. It also usually stops being maintained within a quarter, for the same reason the bought one stops being fed: the hard part was never the schema. The variables that decide whether an internal build pays for itself are in internal AI tool vs vendor for a thirty person biotech.

The third answer: the history writes itself

There is a version where nobody logs anything, and it is not a shared pipeline the whole team feeds. It is single seat, installed for one person, and the record lives in plain files that person owns. Contacts with a partner, adviser, investor or vendor are carded on recurrence by a scheduled pass, hourly at best, from the mail and the meetings that already exist, and it builds the relationship history for you: what they committed to, what you committed to, the dates in play, and every deal or program the relationship touches.

Two consequences matter more than the feature. The first is that your sent mail counts. When you fire off a note that makes a promise or asks for something, the promise is logged, the person who now owes you a reply is recorded, and the follow-up is scheduled before the thread goes cold. The second is that a search stops being a search: have we been round with them before, which term sheet is current, why did that conversation die, all answerable from your own files with the source cited. That is the same engine described in build or buy deal tracking software, seen from the person's side rather than the deal's.

What this looks like in a biotech specifically

The relationships that hurt when you drop them are not evenly distributed. A partner's business development lead asked for the Phase 1 safety package on a call and it was never sent, because everyone assumed somebody else had it. A confidentiality agreement with a diligence-stage partner expires three weeks before the data room is due to close. An investor was told a nonclinical result would land in September, and the study slipped two weeks without anyone connecting the two. Each of those is a relationship fact and a program fact at the same time, which is exactly why a standalone contact database never quite works here, and why the argument for one connected record is made on what an AI company brain is and why a biotech needs one.

So the choice is not really between a bought form and a built one. It is between a record somebody has to remember to update and a record that updates itself, and at forty people only one of those survives a busy quarter. The wider function view is AI for business development in biotech.